skip to main content

Association of Type of Antiepileptic Drugs and Serum Vitamin D Levels among People with Epilepsy

Adelia Putri Maharani  -  Department of Medicine, Faculty of Medicine, Diponegoro University Semarang, Indonesia
Hasna Syariva  -  Department of Medicine, Faculty of Medicine, Diponegoro University Semarang, Indonesia
Dwi Ngestiningsih  -  Department of Medical Biology and Biochemistry, Faculty of Medicine, Diponegoro University Semarang, Indonesia
Arinta Puspita Wati  -  Department of Neurology, Faculty of Medicine, Diponegoro University Semarang, Indonesia
*Santoso Jaeri orcid scopus publons  -  Department of Medical Biology and Biochemistry Faculty of Medicine, Universitas Diponegoro Semarang, Indonesia
Open Access Copyright (c) 2022 Diponegoro International Medical Journal
Creative Commons License This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Citation Format:
Abstract

Background: Epilepsy is a brain disease characterized by repeated unprovoked seizures at least two times with an interval of more than 24 hours between the first seizure and subsequent seizures. Valproic acid is an anti-seizure drug. Long-term use of valproic acid may be associated with metabolic disorders such as weight gain, and lipid profile changes, including vitamin D levels. 

Objectives: To determine the association of type of antiepileptic drugs and serum vitamin D levels among people with epilepsy.

Methods: A cross-sectional study among 24 people with epilepsy was obtained from the outpatient clinic Diponegoro National Hospital Semarang. The subjects were then classified based on the type of antiepileptic drugs into two groups. The first group was subjects who used valproic acid (n=15) and the second group was subjects who used phenytoin (n=9). The demographic and clinical data were collected, then the measurement of vitamin D levels was performed using ELISA. The two independent samples T-test were performed to determine the differences of serum vitamin D levels among people with epilepsy.

Results: The mean of serum vitamin D levels among 24 subjects were 17,32 + 6,37 ng/mL, and the mean of serum vitamin D levels based on the type of antiepileptic drugs were 16,92 + 4.27 ng/mL for the first group and 18 + 9.16 ng/mL for the second group. Furthermore that there was no significant difference in the serum vitamin D levels in both groups (p=0,697).

Conclusion: There is no different effect of valproic acid and phenytoin on the serum vitamin D levels among people with epilepsy.

Note: This article has supplementary file(s).

Fulltext View|Download |  common.other
Ethical Clearance
Subject
Type Other
  Download (528KB)    Indexing metadata

Article Metrics:

  1. Rugg-Gunn F.J. Stapley H.B, Editors. Epilepsy 2021 From Bench to Bedside: A Practical Guide to Epilepsy: Proceeding of XVI ILAE SPR Teaching Weekend: 2017 September 23-24: University of Exford Mathematical Institute. England: Int Leag Against Epilepsy British Chapter. 2017
  2. Nanau RM, Neuman MG. Adverse Drug Reactions Induced by Valproic Acid. Clinical Biochemistry. 2013. DOI: 10.1016/j.clinbiochem.2013.06.012
  3. T Tunnicliff G. Basis of The Antiseizure Action of Phenytoin. General Pharmacology. 1996. DOI: 10.1016/S0306-3623(96)00062-6
  4. He X, Jiang P, Zhu W, Xue Y, Li H, Dang R, et al. Effect of Antiepileptic Therapy on Serum 25(OH)D3 and 24,25(OH)2D3 Levels in Epileptic Children. Ann Nutr Metab. 2016;68(2):119–27. DOI: 10.1159/000443535
  5. Gröber U, Kisters K. Influence of Drugs on Vitamin D and Calcium Metabolism. Dermatoendocrinol [Internet]. 2012;4(2):158–66. DOI: 10.4161/derm.2073
  6. Vrzal R, Doricakova A, Novotna A, Bachleda P, Bitman M, Pavek P, et al. Valproic Acid Augments Vitamin D Receptor-mediated Induction of CYP24 by Vitamin D3: A Possible cause of valproic Acid-induced Osteomalacia? Toxicol Lett [Internet]. 2011;200(3):146–53. DOI: 10.1016/j.toxlet.2010.11.008
  7. WHO Expert Consultation. Appropriate Body-mass Index for Asian Populations and Its Implications for Policy and Intervention Strategies. Lancet (London, England). 2004 Jan;363(9403):157–63
  8. Nagarjunakonda S, Amalakanti S, Uppala V, Rajanala L, Athina S. Vitamin D in Epilepsy: Vitamin D Levels in Epilepsy Patients, Patients on Antiepileptic Drug Polytherapy and Drug-resistant Epilepsy Sufferers. Eur J Clin Nutr [Internet]. 2016;70(1):140–2. DOI: 10.1038/ejcn.2015.127
  9. Ningsih SU, Octaviana F, Soertidewi L, Budikayanti A, Prihartono J. Gambaran Kadar Vitamin D pada Penggunaan Obat Antiepilepsi Generasi Pertama. Neurona. 2013;30(4):1–4
  10. El-Hajj Fuleihan G, Dib L, Yamout B, Sawaya R, Mikati MA. Predictors of Bone Density in Ambulatory Patients on Antiepileptic Drugs. Bone. 2008 Jul;43(1):149–55. DOI: 10.1016/j.bone.2008.03.002
  11. Christakos S, Ajibade D V., Dhawan P, Fechner AJ, Mady LJ. Vitamin D: Metabolism. Endocrinol Metab Clin North Am. 2010;39(2):243–53. DOI: 10.1016/j.ecl.2010.02.002
  12. Teagarden DL, Meador KJ, Loring DW. Low Vitamin D Levels Are Common in Patients with Epilepsy. Epilepsy Res. 2014 Oct;108(8):1352-6. DOI: 10.1016/j.eplepsyres.2014.06.008.Epub2014Jul6.PMID:25060996;PMCID:PMC4149948
  13. Kurniasih D. Hubungan Defisiensi vitamin D dengan Sindrom Metabolik Pada Anak Obes. 2017;20–7
  14. Filardi S, Guerreiro CAM, Magna LA, Neto JFM. Bone Mineral Density, Vitamin D and Anticonvulsant Therapy. Arq Neuropsiquiatr. 2000;58(3 A):616–20. DOI: 10.1590/s0004-282x2000000400003

Last update:

No citation recorded.

Last update:

No citation recorded.